Geert Frederix

Associate Professor

Strategic program(s):

Contact

gfreder2@umcutrecht.nl

Pure profile

Recent publications

All publications

Cost-effectiveness of pre-emptive pharmacogenetic testing Taichi Ochi, Manon G den Uil, Greta Piazza, Geert W J Frederix, Eelko Hak, Vera H M Deneer, Talitha L Feenstra
PLoS ONE, 2026, vol. 21

Choice and impact of EQ-5D-5L value set in cost-utility analyses alongside multinational trials Aniek E M Schouten, Geert W J Frederix, Martijn M Stuiver, Felix Fischer, Anouk E Hiensch, Krister Cromm, Bernard Canaud, Giovanni F M Strippoli, Anne M May, Miriam P van der Meulen,
PLoS ONE, 2026, vol. 21

Cost implications of early treatment discontinuation in cancer H. Colinda Post, Kirsten Opmeer, Tim Schutte, Marijke H. Delsing, Lonneke Timmers, Carla E.M. Hollak, Hanneke W.M. Van Laarhoven, Geert W.J. Frederix
Oncologist, 2026, vol. 31

Early Economic Evaluation of Single Versus Dual Antiplatelet Therapy After Endovascular Revascularization for Peripheral Artery Disease Manon I. Generaal, Emilien C.J. Wegerif, Çağdaş Ünlü, Gert J. de Borst, Geert W.J. Frederix, Miriam P. van der Meulen
Annals of Vascular Surgery, 2026, vol. 122, p.298-308

Patient preferences for pancreatic cancer treatment (PERSEUS) Marjolein F. Lansbergen, Ian P. Smith, Evelien N. van Alphen, Simone Augustinus, Ilse J.M. Fransen, Johanna W. Wilmink, Marc G. Besselink, I. Quintus Molenaar, Marjolein Y.V. Homs, Ignace H.J.T. de Hingh, Bert A. Bonsing, Judith de Vos-Geelen, Brigitte C.M. Haberkorn, Pauline A.J. Vissers, Pythia T. Nieuwkerk, Maarten F. Bijlsma, Geert W.J. Frederix, Hanneke W.M. van Laarhoven,
Health and Quality of Life Outcomes, 2025, vol. 23

Reimbursement routes and past practices for advanced therapy medicinal products in the Netherlands Jurriaan Gort, Christine C van Hattem, Floris Logman, Geert W J Frederix, Lotty Hooft, Lourens T Bloem, Renske M T Ten Ham
Regenerative Medicine, 2025, vol. 20, p.689-706